What is FINRA arbitration?

FINRA arbitration is a method of resolving disputes between investors and brokerage firms or financial advisors outside the court system. It involves a neutral third party, an arbitrator, who reviews the case and makes a binding decision.

Why choose arbitration over litigation?

Arbitration is typically faster, less formal, and more cost-effective than litigation. It also provides a final resolution to disputes, with limited grounds for appeal. Most relationships with financial advisors are formalized by entering into a contract which contains a dispute resolution clause. Nationally, most dispute resolution clauses provide for FINRA arbitration.

Who can file a FINRA arbitration claim?

Investors, brokerage firms, and financial advisors can file a FINRA arbitration claim if they have a dispute related to securities or investment activities. FINRA arbitration is normally the forum for disputes among registered persons, brokerage firms and the public customer clients of the firms.

How do I start the FINRA arbitration process?

To start the arbitration process, Bakhtiari & Harrison will file a Statement of Claim with FINRA, detailing the nature of the dispute, the parties involved, and the relief sought.

What is a Statement of Claim?

A Statement of Claim is a written document submitted by the claimant outlining the facts of the dispute, legal claims, and the desired outcome.

What happens after filing the Statement of Claim?

After filing, the respondent has 45 days to answer the Statement of Claim. The answer must address the claims and may include counterclaims or other relief sought.

What fees are involved in FINRA arbitration?

Fees include filing fees, hearing session fees, and possibly member surcharges or process fees, depending on the specifics of the case.

Can I represent myself in FINRA arbitration?

Yes, you can represent yourself, but many choose to hire an attorney with experience in securities arbitration due to the complexity of the process. Investors and industry professionals who choose to represent themselves do so at a substantial disadvantage, Wall Street firms typically retain experienced professional counsel to represent their interests.

How are arbitrators selected?

Arbitrators are selected through the Neutral List Selection System (NLSS), which provides a list of potential arbitrators. Both parties rank and strike names to agree on a panel.

What qualifications do FINRA arbitrators have?

FINRA arbitrators include attorneys, accountants, financial professionals, and public members who have undergone training and meet FINRA’s qualification standards.

How long does the arbitration process take?

The process typically takes 12-18 months from filing to the final award, but this can vary based on case complexity and scheduling. Preference may be given to investors that are seriously ill or elderly.

What is a prehearing conference?

A prehearing conference is a meeting between the parties and the arbitrators to discuss procedural issues, set a schedule, and address preliminary matters including final FINRA arbitration hearing dates.

What is discovery in arbitration?

Discovery is the exchange of documents and information between the parties to prepare for the hearing. It is more limited than in litigation.

What happens during the arbitration hearing?

During the hearing, both sides present evidence, call witnesses, and make arguments. The arbitrators then deliberate and render a decision.

Is the arbitration hearing open to the public?

No, arbitration hearings are private and confidential. Only the parties, their representatives, and the arbitrators may attend.

Can I settle my case before the hearing?

Yes, parties can settle at any time before the arbitrators render a decision, often through negotiation or mediation.

What is mediation in the context of FINRA arbitration?

Mediation is a voluntary process where a neutral mediator helps the parties negotiate a settlement. It is separate from arbitration and non-binding.

What happens if I lose in arbitration?

If you lose, the arbitrator’s decision is final and binding. There are limited grounds for challenging the award in court.

Can I appeal an arbitration decision?

Generally, you cannot appeal an arbitration decision. However, you can seek to vacate the award on very narrow grounds, such as arbitrator misconduct.

What types of disputes are resolved through FINRA arbitration?

Disputes include claims of fraud, breach of fiduciary duty, negligence, breach of contract, and other issues related to securities and investments.

How are damages determined in arbitration?

Damages are determined based on the evidence presented, including financial records, expert testimony, and the specifics of the case.

Can arbitrators award attorney’s fees?

Arbitrators can award attorney’s fees if provided for by law, contract, or if both parties request it.

How do I enforce an arbitration award?

An arbitration award can be enforced in court through a confirmation process, making it a judgment that can be collected.

What is expungement in FINRA arbitration?

Expungement is the process of removing information from a broker’s record on the Central Registration Depository (CRD) system. It is only granted under specific conditions.

What are the grounds for vacating an arbitration award?

Grounds for vacating an award include arbitrator bias, fraud, corruption, or misconduct, as well as exceeding their powers.

Are arbitration awards public?

Yes, arbitration awards are published on FINRA’s website, providing transparency and access to past decisions.

What is the role of the Office of Dispute Resolution?

The Office of Dispute Resolution administers arbitration and mediation cases, ensuring that the process runs smoothly and efficiently.

What is a Simplified Arbitration?

Simplified Arbitration is for cases involving claims of $50,000 or less, allowing for a quicker and less expensive resolution without a hearing.

Can I request an expedited hearing?

Yes, in certain circumstances, such as elderly or seriously ill parties, you can request an expedited hearing.

What is the role of an arbitrator?

An arbitrator acts as a neutral decision-maker, reviewing evidence, hearing testimony, and issuing a binding decision on the dispute.

How do I prepare for an arbitration hearing?

Preparation involves gathering evidence, preparing witnesses, and developing a clear case strategy to present to the arbitrators.

What types of evidence are admissible in arbitration?

Evidence can include documents, emails, financial records, expert reports, and witness testimony, subject to the arbitrators’ discretion.

Can I request documents from the other party?

Yes, through the discovery process, you can request relevant documents and information from the other party to support your case.

How does FINRA handle conflicts of interest with arbitrators?

FINRA requires arbitrators to disclose any potential conflicts of interest, and parties can object to arbitrators they believe are biased.

What happens if a party does not comply with discovery?

If a party does not comply, the other party can file a motion to compel, asking the arbitrators to order compliance and possibly impose sanctions.

What is a motion in arbitration?

A motion is a formal request for the arbitrators to make a ruling on a specific issue, such as compelling discovery or dismissing a claim.

Can I request interim relief in arbitration?

Yes, you can request interim relief, such as temporary restraining orders or injunctions, to preserve the status quo pending the final decision.

How are hearing locations determined?

Hearing locations are typically determined by the location of the claimant unless both parties agree to a different venue.

What is a telephonic or virtual hearing?

Telephonic or virtual hearings are conducted via phone or video conference, allowing parties to participate remotely.

How are arbitration awards paid?

Awards are typically paid by the losing party within 30 days of the decision, unless otherwise specified by the arbitrators.

What if the losing party does not pay the award?

If the losing party does not pay, you can seek enforcement through the courts, turning the award into a legally enforceable judgment.

Are there any limits on the types of claims I can bring in arbitration?

FINRA arbitration covers a broad range of claims related to securities, but there are some statutory and regulatory limits on certain types of claims.

Can I bring a class action in FINRA arbitration?

No, class actions are not permitted in FINRA arbitration. However, you can join other claimants in a single arbitration if the claims are similar.

What is the role of expert witnesses in arbitration?

Expert witnesses can provide specialized knowledge and opinions to help explain complex financial issues to the arbitrators.

How are hearing dates scheduled?

Hearing dates are scheduled based on availability of the parties and arbitrators, with consideration for the complexity of the case.

Can I request a different arbitrator if I believe one is biased?

Yes, you can challenge an arbitrator if you believe they have a conflict of interest or bias that affects their impartiality.

What is a “chairperson” in a FINRA arbitration panel?

The chairperson is the lead arbitrator who manages the procedural aspects of the case and ensures the hearing runs smoothly.

How does FINRA ensure fairness in arbitration?

FINRA has rules and procedures in place to ensure a fair and impartial process, including arbitrator training and disclosure requirements.

How do I learn more about the FINRA arbitration process?

For more information, you can visit FINRA’s website, contact their Office of Dispute Resolution, or consult with experienced attorneys like those at Bakhtiari & Harrison.

How can Bakhtiari & Harrison help with FINRA arbitration?

Bakhtiari & Harrison can assist with filing claims, responding, selecting arbitrators, discovery, hearings, and ensuring the best possible outcome through skilled representation and strategic advice.

Why San Diego’s Biotechnology Boom Is Creating New Investment Fraud Risk

San Diego is one of the fastest-growing biotechnology and life sciences hubs in the United States. The region’s innovation clusters in La Jolla, Torrey Pines, University City, Sorrento Valley, and Mission Bay attract venture capitalists, startup founders, research scientists, and specialized investors seeking to participate in groundbreaking medical and pharmaceutical discoveries. With cutting-edge research institutions, world-class talent, and a thriving biotech ecosystem, San Diego is home to thousands of early-stage companies working on gene therapy, precision medicine, diagnostics, immuno-oncology, medical devices, and pharmaceutical innovations.

But with explosive growth comes a darker side: an increasing wave of investment fraud tied to biotech ventures that exaggerate clinical results, distort regulatory progress, fabricate scientific claims, or misrepresent financial projections. Investors—especially those without deep scientific or regulatory expertise—are vulnerable to misleading pitches that weaponize complex medical terminology and the promise of transformative cures. San Diego’s biotech ecosystem, although respected, also creates fertile ground for founders who overstate capabilities, conceal risks, or raise funds for products unlikely to survive preclinical testing or FDA review.

This blog examines why biotech investment fraud is rising in San Diego, how misleading claims are made, the common schemes affecting investors, the warning signs to watch for, and how a San Diego investment fraud lawyer helps victims recover losses caused by scientific misrepresentation or securities law violations.

San Diego’s Biotech Ecosystem: Opportunity and Vulnerability

San Diego is home to several unique conditions that make its biotech sector both a driver of innovation and a major target for investment fraud.

1. Scientific Complexity Creates Information Asymmetry

Biotech investors often encounter:

gene-editing terminology
clinical trial results
preclinical data
protein expression charts
toxicology metrics
regulatory pathway descriptions

These scientific details can be difficult for non-experts to evaluate. Founders who misrepresent data may be believed simply because investors cannot independently assess the science.

2. High Capital Requirements Create Fundraising Pressure

Biotech startups may need tens or hundreds of millions of dollars for:

lab equipment
preclinical testing
Phase I–III trials
regulatory submissions
intellectual property protection
manufacturing development

This pressure can push companies to exaggerate progress or hide setbacks.

3. Strong Regional Branding Creates an Illusion of Legitimacy

San Diego investors trust companies affiliated with:

UCSD
Salk Institute
Scripps Research
Sanford Burnham Prebys
JLABS
local biomedical incubators

Even loose connections can give fraudulent companies unearned credibility.

4. Complex FDA Regulations Create Misleading Narratives

Founders often exploit investor uncertainty regarding:

IND status
FDA fast-track designations
orphan drug classifications
breakthrough therapy status
clinical hold risks

Investors may not realize how far a product is from approval.

5. High-Net-Worth Local Population

San Diego’s population includes:

biotech executives
physicians
biomedical researchers
entrepreneurs
retirees with investment portfolios

Fraudsters target these demographics with scientifically appealing but deceptive opportunities.

These conditions combine to create significant investor vulnerability.

Common Biotech and Life Sciences Fraud Schemes in San Diego

Biotech fraud is not always obvious. Some schemes involve deliberate deception, while others involve reckless misrepresentation or omission of material facts.

1. Exaggerated Clinical Trial Results

Founders misstate:

efficacy data
trial endpoints
patient response rates
safety profiles
side effect data

A small or inconclusive trial may be framed as groundbreaking.

2. Misrepresenting FDA Progress

Misleading claims include:

“FDA approval is guaranteed”
“We already have fast-track status”
“The FDA has signaled support for our application”
“We are weeks away from commercialization”

These statements often have no factual basis.

3. Fake or Manipulated Scientific Data

Some companies:

alter lab results
misrepresent mouse model studies
exaggerate biomarker performance
create misleading charts
conceal negative data

Investors may rely heavily on scientific claims that have not been independently validated.

4. Inflated Market Potential

Promoters often overstate:

total addressable market
licensing revenue
insurance reimbursement likelihood
competitive advantage

The economic projections may be completely unrealistic.

5. Misuse of Investor Funds

Fraud includes:

using funds for unrelated ventures
founder enrichment
personal luxury purchases
undisclosed debts
off-book expenses

Biotech companies burn cash quickly, making misuse easy to hide.

6. Fabricated Partnerships or Collaborations

Startups falsely claim partnerships with:

pharmaceutical companies
research hospitals
academic labs
government agencies

In reality, the “partnership” may be nothing more than a single email exchange.

7. Unregistered Securities Offerings

Founders may illegally offer:

private placements
convertible notes
SAFE agreements
equity crowdfunding deals

without proper disclosures or compliance.

8. Misleading Claims About Patents

Red flags include:

patents “pending” but never filed
misrepresented licensing rights
exaggerated IP protection
nonexistent international coverage

Biotech investors often assume patents exist without verification.

These schemes are becoming increasingly common in the San Diego life sciences sector.

Why Investors Fall for Biotech Fraud

Biotech fraud works because it blends scientific credibility with high emotional appeal.

The Promise of Life-Saving Treatment

Investors want to believe in:

cancer breakthroughs
gene-therapy cures
regenerative medicine
Alzheimer’s treatments
anti-aging technologies

The emotional weight of “changing lives” makes investors more receptive.

The Illusion of Scientific Authority

White lab coats, charts, technical jargon, and scientific advisors create trust—even when misleading.

Fear of Missing Out

Early funding rounds promise:

steep valuations
pre-IPO access
licensing deals
long-term recurring revenue

Investors worry about missing the next major biotech winner.

San Diego investors trust recommendations from:

doctors
researchers
biotech executives
professors
peers in the life sciences sector

This trust can be misplaced.

When Biotech Investments Become Securities Violations

Many biotech investments qualify legally as securities. Violations occur when founders:

omit material scientific data
conceal regulatory setbacks
exaggerate clinical results
misuse investor funds
provide false financial projections
sell unregistered securities
mislead investors about risks

Even unintentional misrepresentations may trigger legal liability.

When FINRA Becomes Involved

Some fraudulent biotechnology investments are promoted by licensed financial advisors. When this happens, investors may seek recovery through FINRA arbitration.

Financial advisors violate rules when they:

promote unapproved biotechnology offerings
receive undisclosed compensation
misrepresent risk
fail to conduct due diligence
recommend unsuitable private placements

FINRA may hold firms liable for failure to supervise.

Red Flags of Biotechnology Investment Fraud

Investors should pay attention to warning signs such as:

claims of “revolutionary” or “breakthrough” treatments
no peer-reviewed validation
no published data
vague or inconsistent scientific explanations
high-pressure fundraising tactics
guaranteed returns
unwillingness to discuss FDA challenges
secrecy around data
undisclosed conflicts of interest
refusal to provide offering documents
overly polished but scientifically shallow presentations

Multiple red flags suggest deeper problems.

What Investors Should Do If They Suspect Biotechnology Fraud

Investors should:

Preserve pitch decks, emails, and clinical data presentations
Gather offering documents and financial records
Document inconsistencies in scientific claims
Avoid sending additional funds
Check regulatory filings
Consult a San Diego investment fraud attorney

Biotech cases often depend on detailed documentation.

How a San Diego Investment Fraud Lawyer Helps Victims

A San Diego investment fraud lawyer can:

assess scientific misrepresentations
evaluate FDA regulatory claims
analyze offering documents
determine whether securities laws were violated
trace investor funds
pursue claims in court or arbitration
collaborate with scientific experts
negotiate settlements or restitution

Biotech fraud cases require legal, financial, and scientific expertise.

San Diego’s biotechnology boom brings extraordinary scientific opportunity—but also significant investment risk. When founders misrepresent clinical results, regulatory progress, or scientific capabilities, investors may suffer substantial financial harm. Fortunately, securities laws protect investors from fraudulent or misleading biotech offerings.

If someone invested in a San Diego biotechnology startup and believes they were misled, a San Diego investment fraud lawyer can help evaluate the misconduct and pursue recovery.

For confidential support, contact Bakhtiari & Harrison.